SCHEMBL30775282

SCHEMBL30775282

O=C1NCc2c1cccc2-c1ccc(CO)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.58
PIK3CD O00329 1/20 0.54
PIK3CA P42336 1/20 0.54
PIK3CB P42338 1/20 0.54
PIM1 P11309 3/20 0.51
ROCK1 Q13464 3/20 0.51
CLK4 Q9HAZ1 3/20 0.51
CDK5 Q00535 2/20 0.51
DYRK1A Q13627 2/20 0.51
CSNK1A1 P48729 1/20 0.51
LRRK2 Q5S007 1/20 0.51
DYRK1B Q9Y463 1/20 0.51
ROCK2 O75116 3/20 0.51
MAP4K4 O95819 2/20 0.51
LCK P06239 2/20 0.51
RET P07949 2/20 0.51
RPS6KB1 P23443 2/20 0.51
BLK P51451 2/20 0.51
STK3 Q13188 2/20 0.51
NTRK3 Q16288 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28224571 0.86 KDR (0.62) KDRPIK3CDPIK3CAPIK3CBPIM1
SCHEMBL19608227 0.83 PIK3CD (0.64) KDRPIK3CDPIK3CAPIK3CBPIM1
SCHEMBL30331758 0.81 PARP10 (0.69) KDRPIK3CDPIK3CAPIK3CBPIM1
SCHEMBL1333209 0.80 KDR (0.57) KDRPIK3CDPIK3CAPIK3CBPIM1
SCHEMBL28223904 0.80 PIK3CD (0.64) KDRPIK3CDPIK3CAPIK3CBPIM1
SCHEMBL29845432 0.78 CLK4 (0.57) KDRPIK3CDPIK3CAPIK3CBPIM1
SCHEMBL30775223 0.77 CLK4 (0.51) KDRPIK3CDPIK3CAPIK3CBPIM1
SCHEMBL30775306 0.77 PIK3CD (0.50) KDRPIK3CDPIK3CAPIK3CBPIM1
SCHEMBL30543353 0.76 KDR (0.62) KDRPIK3CDPIK3CAPIK3CBPIM1
SCHEMBL30775285 0.76 KDR (0.57) KDRPIK3CDPIK3CAPIK3CBPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR KDR 4622/4885PIK3CD 1653/4885PIK3CA 1073/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR KDR 4622/4885PIK3CD 1653/4885PIK3CA 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.